Toussirot E, Vauchy C, Binda D, Michel F. Drug Des Devel Ther. 2016;10:2087–2094.
On page 2089, a column heading in Table 1 was incorrectly presented. The last column heading was presented as “Golimumab 60 mg”, whereas this should have been presented as “Golimumab 100 mg” as shown below:
Table 1.
Proportion of ASAS20 responders in the GO-RAISE and GO-AHEAD studies
| Study | Placebo | Golimumab 50 mg | Golimumab 100 mg |
|---|---|---|---|
| GO-RAISE, primary end point at Week 1415 | 21.8 | 59.4 | 60 |
| GO-RAISE, 2 years17 | 38.5 | 60.1 | 71.4 |
| GO-AHEAD, primary end point at Week 1616 | 40 | 71.1 | NA |
Abbreviations: ASAS, Assessment of SpondyloArthritis international Society; NA, not available.